The stock of Hims & Hers Health Inc. (NYSE:HIMS) last traded at $7.44, down -5.82% from the previous session.
Data from the available sources indicates that Hims & Hers Health Inc. (NYSE:HIMS) is covered by 10 analysts. The consensus rating among analysts is ‘Overweight’. As we calculate the median target price by taking the range between a high of $18.00 and a low of $10.00, we find $12.50. Given the previous closing price of $7.90, this indicates a potential upside of 58.23 percent. HIMS stock price is now -14.54% away from the 50-day moving average and -10.90% away from the 200-day moving average. The market capitalization of the company currently stands at $1.57B.
In total, 4 analysts have assigned it a hold rating, and 6 have given it a buy rating. Brokers who have rated the stock have averaged $12.80 as their price target over the next twelve months.
With the price target of $11, TD Cowen recently initiated with Outperform rating for Hims & Hers Health Inc. (NYSE: HIMS).
In other news, Baird Melissa, Chief Operating Officer sold 9,133 shares of the company’s stock on Aug 07. The stock was sold for $73,052 at an average price of $8.00. Upon completion of the transaction, the Chief Operating Officer now directly owns 426,751 shares in the company, valued at $3.18 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Aug 04, Chief Operating Officer Baird Melissa sold 9,133 shares of the business’s stock. A total of $74,732 was realized by selling the stock at an average price of $8.18. This leaves the insider owning 435,884 shares of the company worth $3.24 million. Insiders disposed of 11,481,296 shares of company stock worth roughly $85.42 million over the past 1 year. A total of 0.80% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in HIMS stock. A new stake in Hims & Hers Health Inc. shares was purchased by SAMLYN CAPITAL, LLC during the first quarter worth $13,043,000. DRIEHAUS CAPITAL MANAGEMENT LLC invested $12,449,000 in shares of HIMS during the first quarter. In the first quarter, PRUDENTIAL FINANCIAL INC acquired a new stake in Hims & Hers Health Inc. valued at approximately $6,520,000. BALYASNY ASSET MANAGEMENT L.P. acquired a new stake in HIMS for approximately $4,363,000. AMERIPRISE FINANCIAL INC purchased a new stake in HIMS valued at around $3,935,000 in the second quarter. In total, there are 269 active investors with 58.20% ownership of the company’s stock.
With an opening price of $9.26 on Tuesday morning, Hims & Hers Health Inc. (NYSE: HIMS) set off the trading day. During the past 12 months, Hims & Hers Health Inc. has had a low of $4.01 and a high of $12.34. As of last week, the company has a debt-to-equity ratio of 0.00, a current ratio of 4.00, and a quick ratio of 3.60. The fifty day moving average price for HIMS is $8.67 and a two-hundred day moving average price translates $8.37 for the stock.
The latest earnings results from Hims & Hers Health Inc. (NYSE: HIMS) was released for Mar, 2023. According to the Household & Personal Products Company, earnings per share came in at -$0.03, beating analysts’ expectations of -$0.05 by 0.02. This compares to -$0.10 EPS in the same period last year. The net profit margin was -9.70% and return on equity was -19.00% for HIMS. The company reported revenue of $207.91 million for the quarter, compared to $113.56 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 83.08 percent. For the current quarter, analysts expect HIMS to generate $213.78M in revenue.
Hims & Hers Health Inc.(HIMS) Company Profile
Hims & Hers Health, Inc. operates a telehealth platform that connects consumers to licensed healthcare professionals. The company offers a range of health and wellness products and services available to purchase on its websites and mobile application directly by customers. It also provides prescription medication on a recurring basis and ongoing care from healthcare providers; and over-the-counter drug and device products, cosmetics, and supplement products, primarily focusing on wellness, sexual health and wellness, skincare, and hair care. The company’s curated non-prescription products include vitamin C, melatonin, biotin, and collagen protein supplements in the wellness category; moisturizer, serums, and face wash in the skincare category; condoms, climax delay spray and wipes, vibrators, and lubricants in the sexual health and wellness category; and shampoos, conditioners, scalp scrubs, and topical treatments, such as minoxidil in the hair care category. In addition, it offers medical consultation services, as well as health and wellness products through wholesale partners. The company is based in San Francisco, California.
